Product Indication In vitro Confirmationof Lead Candidate Efficacy Study inAnimal Model Candidate Confirmation Pre-clinical Clinical Bispecific Antibody MOBIT:Monovalent Bi-Targeting Antibody BAB-05 Hematological malignancies Pre-clinical---IND expected in 2025-Q4 BAB-09 Prostate Cancer Pre-clinical BAB-0120 NSCLC Pre-clinical DIMA:Immune Checkpoint Inhibitor-Antibody Fusion AF-29 Autoimmune and Inflammatory diseases Pre-clinical--- IND expected in 2025-Q4 ICiAF:Tumor-relevant Immune Effector cell Modulator BIC-020 Colorectal Cancer Pre-clinical BIC-021 HSNCC/solid tumor Candidate Confirmation TrIEM:Directed Immune Modulatory Antibody lCM-053 Solid/Hematological cancer Pre-clinical ICM-022 Castration -resistant prostate cancer Pre-clinical ICM-051 Solid cancer Candidate Confirmation Bispecific Antibody Conjugates Bs-ADC BTA-010 NSCLC Pre-clinical---IND expected in 2026-Q1 BTA-032 Prostate Cancer Candidate Confirmation BTA-0120 AML Efficacy Study in Animal Model Recombinant Proteins Long-Acting Protein LTP-03 Obesity/Diabetes Pre-clinical LTP-0401 Analgesia Pre-clinical Monoclonal Antibodies Epitope-directed mAbs MAB105 Immune modulator/Sepsis/RA Pre-clinical